Efficacy of cisplatin-based combinations in chemoradiation therapy of cervical cancer


Cite item

Full Text

Abstract

Introduction. High incidence of stage III-IV cervical cancer and high recurrence rate after treatment causes scientific research of alternative approach in patient’s treatment. Objective - improvement results of treatment patients with locally advanced cervical cancer (LACC). Materials and methods. 101 patients with T2b-3bN0-1M0-1 cervical cancer (M1 - paraaortic lymph nodes metastases by radiologic exam) received concurrent chemoradiation therapy followed by adjuvant chemotherapy (CT). External-beam conformal radiation therapy (EBRT) on pelvic and regional lymph nodes 50 Gy (25 fractions) with weekly chemotherapy: arm A - cisplatin 20 mg/m2 + paclitaxel 30 mg/m2, arm В - cisplatin 20 mg/m2 + irinotecan 20 mg/m2, arm C - cisplatin 40 mg/m2. Brachytherapy 30 Gy (4 fractions) following ERBT. In arm A and В after chemoradiation therapy patient received 2 cycles of adjuvant CT: paclitaxel 175 mg/m2 + cisplatin 75 mg/m2 every 3 weeks or irinotecan 65 mg/m2 on day 1 and 8 + cisplatin 75 mg/m2 on day 1 every 3 weeks. Results. All regimens shows high efficacy: objective responses in arm A obtained 96,9%, in arm В - 100%, in arm C - 100%. Median overall survival (OS) and progression free survival (PFS) in all arms not obtained. PFS at 1 year was significantly improved in arm A and В versus arm C: IIIb stage (arm A vs arm C, p=0,036; arm В vs arm C, p=0,005), pelvic lymph node metastases (arm В vs arm C, p=0,013), low-differentiation tumors (arm В vs arm C, p=0,013). 1-year OS did not shows improvement. Toxicity of all three regimens was tolerable. Conclusions. Our regimens showed high efficacy and tolerable toxicity. Significantly improvement in 1-year recurrence rate in poor-prognostic group of patients obtained encouraging results. Pending of medians OS and PFS allows to make the final conclusion about the benefits of combination chemoradiation therapy with adjuvant chemotherapy in LACC.

About the authors

I Ya Bazaeva

N.N.Blokhin Russian Cancer Research Center

Email: irinabazaeva@rambler.ru
аспирант отд-ния химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

V A Gorbounova

N.N.Blokhin Russian Cancer Research Center

д-р мед. наук, проф., зав. отд. химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

O A Kravets

N.N.Blokhin Russian Cancer Research Center

д-р мед. наук, вед. науч. сотр. отд-ния радиохирургии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

S V Khokhlova

N.N.Blokhin Russian Cancer Research Center

канд. мед. наук, ст. науч. сотр. отд-ния химиотерапии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

E A Romanova

N.N.Blokhin Russian Cancer Research Center

аспирант отд-ния радиохирургии ФГБУ РОНЦ им. Н.Н.Блохина 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23

References

  1. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). М.: МНИОИ им. П.А.Герцена, 2015.
  2. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2013 г. М.: РОНЦ им. Н.Н.Блохина, 2014.
  3. American Cancer Society. Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society. 2014; p. 22-3.
  4. Chemoradiotherapy for Cervical Cancer Meta-Analisis Collaboration (CCCMAC). Reducing Uncertainties About the Effects of Chemoradiotherapy for Cervical Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 18 Randomized Trials. J Clin Oncol 2008; 26 (35): 5802-12.
  5. Wiebe E, Denny L, Thomas G. FIGO cancer report 2012. Cancer of the cervix uteri. Int J Gynecol Obstet 2012; 119 (2): 100-10.
  6. Cueva J.F, Martinez-Lago M, Vieito M et al. Neoadjuvant chemoherapy followed by chemoradiation in selected locally advanced squamous cervical cancer. J Clin Oncol 2013. Abstract 5603.
  7. Fabbro M, Gladieff L, Guichard F et al. Phase I study of irinotecan and cisplatin in combination with pelvic radiotherapy in the treatment of locally advanced cervical cancer: A GINECO trial. Gynecol Oncol 2010; 117: 276-80.
  8. Mc Cormack M, Kadalayil L, Hackshaw A et al. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer 2013; 108 (12): 2464-9.
  9. Nagai Y, Toita T, Wakayama A et al. Concurrent chemoradiotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix. Anticancer Res 2012; 32 (4): 1475-9.
  10. Pu J, Qin S.S, Ding J.X et al. A randomized controlled study of single - agent cisplatin and radiotherapy versus docetaxel/cisplatin and radiotherapy in high - risk early - stage cervical cancer after radical surgery. J Cancer Res Clin Oncol 2013; 139 (4): 703-8.
  11. Rose P.G, Sill M.W, Mc Meekin D.S. A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study. Gynecol Oncol 2012; 125 (1): 158-62.
  12. Varghese S.S, Ram T.S, Pavamani S.P et al. Concurrent chemo - irradiation with weekly cisplatin and paclitaxel in the treatment of locally advanced squamous cell carcinoma of cervix: a phase II study. J Cancer Res Ther 2014; 10 (2): 330-6.
  13. Petrelli F, De Stefani A, Raspagliesi F et al. Radiotherapy with concurrent cisplatin - based doublet or weekly cisplatin for cervical cancer: A systematic review and meta - analysis. Gynecol Oncol 2014; 134 (Issue 1): 166-71.
  14. Mileshkin L.R. A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: Outback (ANZGOG0902/GOG0274/RTOG1174). 2014 ASCO Annual Meeting. Abstract TPS5632.
  15. Duenas-Gonzalez A, Zarba J.J, Patel F et al. Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix. J Clin Oncol 2011; 29 (13): 1678-85

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies